Dr. Gregory E. Holt, MD
Pulmonology (Pulmonary Disease Physician)
- Medicare participating
At a glance
- Medical school
- Loyola University of Chicago, Stritch School of Medicine (2002)
- Years since graduation
- 24
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 70
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2002Medical school: Loyola University of Chicago, Stritch School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pulmonary Disease Physician primary
FL license ME 108849 -
Critical Care Medicine (Internal Medicine) Physician
FL license ME 108849 -
Internal Medicine Physician
FL license ME 108849
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Jackson Health System Miami, FL
Medical groups
- University of Miami (2,377 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 70
- Services billed
- 145
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Critical care, first 30-74 minutes | 51 | 24 |
| Established patient office or other outpatient visit, 30-39 minutes | 45 | 27 |
| Established patient office or other outpatient visit, 20-29 minutes | 13 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Miami, FL | 66 |
| Symbicort (budesonide/formoterol fumarate) Other prescribers in Miami, FL | 42 |
| Breo Ellipta (fluticasone/vilanterol) Other prescribers in Miami, FL | 28 |
| Montelukast Sodium Other prescribers in Miami, FL | 23 |
| Spiriva Handihaler (tiotropium bromide) Other prescribers in Miami, FL | 17 |
| Azithromycin Other prescribers in Miami, FL | 16 |
| Trelegy Ellipta (fluticasone/umeclidin/vilanter) Other prescribers in Miami, FL | 15 |
| Budesonide-Formoterol Fumarate (budesonide/formoterol fumarate) Other prescribers in Miami, FL | 13 |
| Combivent Respimat (ipratropium/albuterol sulfate) Other prescribers in Miami, FL | 12 |
| Ethambutol Hcl | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $16.00 in total to this clinician.
| Pulmonx Corporation | $16.00 |
|---|
| Food and Beverage | $16.00 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $36,875 in research payments for these studies, mostly to the institutions running them.
- A Phase III Randomized Double blind Multicenter Global Study of Rilvegostomig or Pembrolizumab in Combination with Platinum based Chemotherapy for the First line Treatment of Patients with Metastatic Non squamous Non …
AstraZeneca Pharmaceuticals LP - Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Mirati Therapeutics, Inc. · Recruiting · NCT04613596
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.